[{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"971ccbcc-807b-4f19-a719-95e21b179631","acronym":"C4551001","url":"https://clinicaltrials.gov/study/NCT04606446","created_at":"2021-01-19T20:31:32.792Z","updated_at":"2025-02-25T16:53:21.614Z","phase":"Phase 1","brief_title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04606446 - C4551001","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER • CDKN2A","pipe":" | ","alterations":" ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 08/13/2025","primary_completion_date":" 08/13/2025","study_txt":" Completion: 03/07/2027","study_completion_date":" 03/07/2027","last_update_posted":"2025-02-04"},{"id":"f1019130-1357-4f9c-93ac-a373d891ebad","acronym":"ReDiscover","url":"https://clinicaltrials.gov/study/NCT05216432","created_at":"2022-02-05T18:28:00.435Z","updated_at":"2025-02-25T17:37:34.946Z","phase":"Phase 1","brief_title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer","source_id_and_acronym":"NCT05216432 - ReDiscover","lead_sponsor":"Relay Therapeutics, Inc.","biomarkers":" HER-2 • PIK3CA • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • zovegalisib (RLY-2608) • atirmociclib (PF-07220060)"],"overall_status":"Recruiting","enrollment":" Enrollment 890","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-29"},{"id":"acacd99a-fb40-4fcc-bf29-f2cc0dc2ec5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06105632","created_at":"2023-10-27T17:14:14.954Z","updated_at":"2024-07-02T16:34:59.008Z","phase":"Phase 3","brief_title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","source_id_and_acronym":"NCT06105632","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • fulvestrant • exemestane • atirmociclib (PF-07220060)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 01/09/2024","start_date":" 01/09/2024","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/14/2028","study_completion_date":" 12/14/2028","last_update_posted":"2024-06-04"}]